Acrotech Biopharma Drug Patent Portfolio

Acrotech Biopharma owns 5 orange book drugs protected by 14 US patents with Fusilev having the least patent protection, holding only 1 patent. And Evomela with maximum patent protection, holding 7 patents. Given below is the list of Acrotech Biopharma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11541012 Compositions comprising disodium levofolinate 25 Mar, 2039
Active
US10040872 Alkylated cyclodextrin compositions and processes for preparing and using the same 30 Jan, 2034
Active
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
Active
US10940128 Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same 14 Jun, 2030
Active
US10864183 Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same 28 May, 2030
Active
US11020363 Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same 28 May, 2030
Active
US8410077 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US9200088 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
Active
US8835501 Pharmaceutical formulations of HDAC inhibitors 27 Oct, 2027
Active
US6888027 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors 10 Aug, 2026
Active
US7622470 Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin 31 May, 2025
Active
US8299078 Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin 31 May, 2025
Active
US6028071 Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors 16 Jul, 2022 Expired
US6500829 Substantially pure diastereoisomers of tetrahydrofolate derivatives 07 Mar, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Acrotech Biopharma.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 17 Jun, 2024 US10864183
Payment of Maintenance Fee, 8th Year, Large Entity 30 Apr, 2024 US9493582
Payment of Maintenance Fee, 12th Year, Large Entity 30 Apr, 2024 US8299078 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 17 May, 2023 US9200088
Email Notification 31 Mar, 2023 US11541012
Electronic Review 31 Mar, 2023 US11541012
Mail O.P. Petition Decision 31 Mar, 2023 US11541012
Mail-Petition Decision - Dismissed 27 Mar, 2023 US11541012
Petition Decision - Dismissed 24 Mar, 2023 US11541012
O.P. Petition Decision 08 Mar, 2023 US11541012
Petition Decision - Accept Late Payment of Maintenance Fees - Granted 02 Mar, 2023 US8835501
Petition to Accept Late Payment of Maintenance Fee Payment Filed 02 Mar, 2023 US8835501
Surcharge, Petition to Accept Pymt After Exp, Unintentional 02 Mar, 2023 US8835501
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 02 Mar, 2023 US8835501
Payment of Maintenance Fee, 8th Year, Large Entity 02 Mar, 2023 US8835501


Acrotech Biopharma's Drug Patent Litigations

Acrotech Biopharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 09, 1998, against patent number US6500829. The petitioner , challenged the validity of this patent, with WOOD et al as the respondent. Click below to track the latest information on how companies are challenging Acrotech Biopharma's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6500829 March, 1998 Decision
(28 Sep, 2001)
WOOD et al


Acrotech Biopharma's Family Patents

Acrotech Biopharma drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 26.6% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Acrotech Biopharma Drug List

Given below is the complete list of Acrotech Biopharma's drugs and the patents protecting them.


1. Beleodaq

Beleodaq is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8835501 Pharmaceutical formulations of HDAC inhibitors 27 Oct, 2027
(3 years from now)
Active
US6888027 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors 10 Aug, 2026
(1 year, 10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Beleodaq's drug page


2. Evomela

Evomela is protected by 7 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10040872 Alkylated cyclodextrin compositions and processes for preparing and using the same 30 Jan, 2034
(9 years from now)
Active
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
(8 years from now)
Active
US10940128 Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same 14 Jun, 2030
(5 years from now)
Active
US10864183 Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same 28 May, 2030
(5 years from now)
Active
US11020363 Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same 28 May, 2030
(5 years from now)
Active
US8410077 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(4 years from now)
Active
US9200088 Sulfoalkyl ether cyclodextrin compositions 13 Mar, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evomela's drug page


3. Folotyn

Folotyn is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7622470 Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin 31 May, 2025
(7 months from now)
Active
US8299078 Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin 31 May, 2025
(7 months from now)
Active
US6028071 Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors 16 Jul, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Folotyn's drug page


4. Fusilev

Fusilev is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6500829 Substantially pure diastereoisomers of tetrahydrofolate derivatives 07 Mar, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fusilev's drug page


5. Khapzory

Khapzory is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11541012 Compositions comprising disodium levofolinate 25 Mar, 2039
(14 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Khapzory's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List